Axitirome

Drug Profile

Axitirome

Alternative Names: CGP 26214; CGS 26214

Latest Information Update: 30 Apr 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antihyperlipidaemics
  • Mechanism of Action LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 25 Jan 2000 CGS 26214 is now called Axitirome
  • 12 Nov 1997 A study in volunteers has been added to the adverse events and pharmacokinetics sections
  • 16 Apr 1996 Phase-I clinical trials for Hyperlipidaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top